Regeneron’s Fianlimab Flop Rewrites the LAG-3 Playbook — and Bristol-Myers Just Got Luckier
Regeneron's Phase 3 fianlimab trial misses in first-line melanoma, threatening a key pipeline asset and handing Opdualag a competitive...
immuno-oncology
Innovent’s Triple Breakthrough Play: IBI363 Just Became the Most Dangerous Asset in Immuno-Oncology’s Coldest Corner
Innovent's IBI363 scores its third NMPA Breakthrough Therapy Designation—this time for MSS/pMMR colorectal cancer, the tumor type that killed...
China Biotech Dealmaking Shifts from Opportunistic to Strategic
At BIO-Europe Spring 2026, industry leaders from AstraZeneca, Kelun-Biotech, Harbour BioMed, and Panacea Capital dissected the structural forces driving...